Background
Rationale
Aim and objectives
Methods
Registration and protocol
Eligibility criteria
PICOS | Inclusion criteria | Exclusion criteria |
---|---|---|
Population | Patients from any country undergoing elective surgery | Patients undergoing emergency surgery or non-surgical treatments (e.g. chemotherapy) |
Intervention | A preoperative prehabilitation programme (any setting), defined as a (set of) intervention(s) aimed at optimising functioning and reducing disability in individuals awaiting surgery. The intervention(s) had to include at least one component of physio- or occupational therapy and at least one in-person meeting between the patient(s) and health care professional(s). The ‘dose’, i.e. the programme’s duration (overall and per session) and frequency, had to be sufficiently longa to have an effect if the patients fully adhered to it | Purely medical/nutritional interventions, an intervention combined with additional postoperative rehabilitation, cognitive behaviour therapy or health counselling/education alone, purely web/app-based prehabilitation programmes |
Control | Usual preoperative care as defined by the study authors, i.e. the routine care that patients with a given condition receive in the respective hospital (extended only by the baseline measurements performed as part of the trial) | Another prehabilitation intervention; no comparator |
Outcome | Clinical effectiveness and costs, any timeframe for follow-up | Clinical effectiveness only |
Study type | Full (i.e. cost–benefit, cost-effectiveness and cost–utility analyses) or partial economic evaluations (i.e. cost-minimization analysis), trial-basedb or model-based economic evaluations regardless of their statusc, cost perspective, publication year, language and type (i.e. full article, conference abstract) | Systematic reviews, simple, non-comparative cost analyses (i.e. studies that only calculated the costs of the intervention), commentaries/letters, animal studies |
Information sources
Search strategy
Selection process
Data collection process
Data items
Risk of bias and methodological quality assessment
Effect measures
Synthesis methods
Assessment of publication bias
Results
Study selection
Characteristics of economic evaluations
Study ID, main referencea | Type and design of analysis | Perspective | Location (city/ cities; country) | Enrolment periodb | Inclusion criteria (disease(s); type(s) of surgery; criteria for increased perioperative risk) | Population demographics | Number of patients randomised (total (IG vs. CG)) |
---|---|---|---|---|---|---|---|
AlShewaier 2016 [37] | CUA; trial-based (RCT) | Unclear | Riyadh; Saudi Arabia | 07/2014–01/2015 | Isolated ACL injury; ACL reconstruction | Female: 0%, male: 100% Median age: 27 years | 84 (39 vs. 45) |
Barberan-Garcia 2019 [38] | CCA; trial-based (RCT) | Mix of payer/provider perspective | Barcelona; Spain | 02/2013–06/2016 | Not specified; major digestive surgery; age > 70 years and/or ASA score ≥ III | Female: 25%, male: 75% Mean age: 71 years | 125 (62 vs. 63) |
Beaupre 2004 [39] | CMA; trial-based (RCT) | Payer perspective | Edmonton; Canada | Not reported | Non-inflammatory arthritis; primary TKA | Female: 55%, male: 45% Mean age: 67 years | 131 (65 vs. 66) |
Chen 2022 [40] | CBA; model-based (projection) | Provider perspective | Toronto; Canada | Not applicable (model) | Not specified; major elective intra-cavity surgery; higher-than-average risk, limited physiologic reserve, frailty, deconditioned patient, other indication for prehabilitation with explanation | Not reported | 480 (240 vs. 240) |
Dholakia 2021 [41] | CEA; model-based (decision tree) | Payer perspective | Not reported; USA | Not applicable (model) | Epithelial ovarian cancer; non-emergent primary debulking surgery; frailty | Female: 100%, male: 0% Age not reported | 8830 (4415 vs. 4415) |
Englesbe 2017 [29] | CMA; trial-based (NRSI) | Mix of payer/provider perspective | Ann Arbor; USA | IG: 06/2014–12/2015c CG: 07/2006–06/2011 | Not specified; major inpatient abdominal and thoracic operative care | Female: 50%, male: 50% Mean age: 60 years | 364 (182 vs. 182) |
Fernandes 2017 [42] | CUA; trial-based (RCT) | Mix of payer/ provider/patient perspective | Svendborg; Denmark | 01/2010–03/2011 | Symptomatic osteoarthritis; TKA, THA | Female: 56%, male: 44% Mean age: 67 years | 165 (84 vs. 81) |
Gao 2015 [43] | CCA; trial-based (NRSI) | Unclear | Chengdu; China | 11/2008–06/2011 | Lung cancer; lobectomy; > 800 pack-years, quitted smoking < 2 weeks ago, bronchial hyperresponsiveness, impaired lung function | Female: 59%, male: 41% Mean age: 66 years | 142 (71 vs. 71) |
Gränicher 2020 [44] | CCA; trial-based (RCT) | Payer perspective | Zürich; Switzerland | 07/2016–03/2017 | Not specified; TKA | Female: 40%, male: 60% Mean age: 67 years | 20 (10 vs. 10) |
Howard 2019 [30] | CCA; trial-based (NRSI) | Mix of payer/ provider perspective | Ann Arbor; USA | 01/2012–12/2017c | Not specified; major abdominal surgery | Female: 49%, male: 51% Mean age: 59 years | 116 (76 vs. 40) |
Huang 2012 [45] | CCA; trial-based (RCT) | Provider perspective | Changhua; Taiwan | 01/2008–12/2010 | Advanced osteoarthritis; primary TKA | Female: 72%, male: 28% Mean age: 70 years | 243 (126 vs. 117) |
Koh 2021 [46] | CCA; trial-based (NRSI) | Patient perspective | Singapore; Singapore | IG: 02/2017–03/2020 CG: 04/2016–09/2018 | Colorectal cancer; major colectomy; age ≥ 70 years | Female: 44%, male: 56% Median age: 78 years | 81 (58 vs. 23) |
Lai 2017 [32] | CCA; trial-based (RCT) | Unclear; assumed provider perspective | Chengdu; China | 01/2015–12/2015d | Non-small cell lung cancer; lung cancer surgery; > 20 pack-years, age > 75 years, BMI > 30, impaired predicted lung function or COPD | Female: 42%, male: 58% Mean age: 64 years | 101 (51 vs. 50) |
Lai 2019 [33] | CCA; trial-based (RCT) | Unclear; assumed provider perspective | Chengdu; China | 01/2018-not reported | Non-small cell lung cancer; lobectomy | Female: 51%, male: 49% Mean age: 64 years | 68 (34 vs. 34) |
McGregor 2004 [47] | CEA; trial-based (RCT) | Mix of payer/provider perspective | London; UK | Not reported | Not specified; THA | Female: 71%, male: 29% Mean age: 72 years | 39 (19 vs. 20) |
Mouch 2019 [31] | CMA; trial-based (NRSI) | Mix of payer/provider perspective | Multiple cities in Michigan; USA | 01/2014–12/2017c | Not specified; various types of surgery; high risk for complications (according to surgeon) | Female: 53%, male: 47% Median age: 70 years | 1569 (523 vs. 1046) |
Nguyen 2022 [48] | CUA; trial-based (RCT) | Mix of payer/provider perspective | Paris, Clermont-Ferrand; France | 10/2012- not reported | Knee osteoarthritis; TKA | Female: 68%, male: 32% Mean age: 69 years | 262 (131 vs. 131) |
Pham 2016 [49] | CMA; trial-based (RCT) | Unclear; assumed provider perspective | Sudbury; Canada | Not reported | Osteoarthritis; TKA, THA; BMI ≥ 30 | Female: 69%, male: 31% Mean age: 64 years | 50 (29 vs. 21) |
Ploussard 2020 [50] | CCA; trial-based (NRSI) | Mix of payer/provider perspective | Quint-Fonsegrives; France | IG: 01/2018–12/2019 CG: 01/2016–12/2017 | Not specified; robot-assisted radical prostatectomy | Female: 0%, male: 100% Mean age: 66 years | 350 (194 vs. 156) |
Risco 2022 [51] | CCA; trial-based (NRSI) | Provider perspective | Barcelona, Spain | 06/2017–12/2019 | Not specified; major digestive, cardiac, thoracic, gynaecologic or urologic surgeries; age > 70 years and/or ASA score ≥ III and/or severe deconditioning | Female: 69%, male: 31% Median age 71 years | 656 (328 vs. 328) |
Tew 2017 [52] | CEA; trial-based (RCT) | Mix of payer/provider perspective | Middlesbrough, Sheffield, York; UK | 09/2013–07/2015 | Abdominal aortic aneurysms; abdominal aortic aneurysm repair | Female: 6%, male: 94% Mean age: 75 years | 53 (27 vs. 26) |
Tveter 2020 [53] | CUA; trial-based (RCT) | Unclear; assumed mix of provider, payer and patient perspective | Trondheim, Bergen, Haugesund; Norway | 04/2013–06/2015 | Carpometacarpal joint osteoarthritis; thumb carpometacarpal joint surgery | Female: 79%, male: 21% Mean age: 63 years | 180 (90 vs. 90) |
Van Wijk 2020 [54] | CBA; model-based (decision tree) | Not reported | Netherlands (nationwide) | Not applicable (model) | Not specified; pancreatic surgery; low physical fitness, impaired nutritional status, the presence of iron deficiency anaemia, frailty, and/or intoxications | Not reported | Not reported |
Wang 2020 [55] | CCA; trial-based (NRSI) | Unclear; assumed provider perspective | Singapore; Singapore | 02/2016–10/2017 | Hepatocellular carcinoma, colorectal liver metastases; liver resection | Female: 26%, male: 74% Median age: 67 years | 104 (70 vs. 34) |
Zhou 2017 [34] | CCA; trial-based (NRSI) | Unclear; assumed patient perspective | Chengdu; China | 03/2014–06/2015d | Primary non-small cell lung cancer; lobectomy; ≥ 20 pack-years, BMI ≥ 28, impaired lung function, COPD/asthma/airway hyper reactivity | Female: 56%, male: 44% Mean age: 59 years | 939 (197 vs. 742) |
Methods of economic evaluations
Description of prehabilitation programmes
Study ID, main reference | Type and modalities | Involved health care professionals | Setting | Overall duration, frequency and duration per sessiona | Intensity of exercise trainingb | Evidence-based programme | Programme costs in EUR (2020) |
---|---|---|---|---|---|---|---|
AlShewaier 2016 [37] | Unimodal: exercise (resistance, proprioception and balance) | Physiotherapists | Outpatient—hospital | 4 weeks, 3x/week, for 45 min | High | Yes | 838 |
Barberan-Garcia 2019 [38] | Multimodal: counselling/education, exercise (endurance), promotion of physical activity | Specialised physiotherapist | Outpatient—hospital | Individual, but min 4 weeks, 1–3x/week, individual session duration | High | Yes | 457 |
Beaupre 2004 [39] | Multimodal: counselling/education, exercise (resistance) | Physiotherapists | Outpatient—community | 4 weeks, 3x/week, individual and progressing session duration | High | No | 225 |
Chen 2022 [40] | Multimodal: exercise (endurance, resistance, disease-specific), nutrition (counselling, supplements), psychosocial (stress management), smoking cessation | Kinesiologist or certified exercise physiologist, dietitian, psychologist | Outpatient—hospital (FBP group), home (HBP group) | Individual; min 2 weeks, 2x/week (FBP), 3–5x/week (HBP), for 60 min | Moderate | Yes | 798 |
Dholakia 2021 [41] | Various (model): smoking cessation, stabilising diseases, nutrition (counselling, supplements), exercise (endurance, resistance, inspiratory muscles), psychosocial (stress management), counselling/education, other (social/financial support) | Variable (model) | Variable (model) | Variable (model) | Not applicable | No | Variable (model) |
Englesbe 2017 [29] | Multimodal: promotion of physical activity, exercise (inspiratory muscles), nutrition (counselling), psychosocial (stress management), planning of care, smoking cessation | Not reported | Home | Individual; min 2 weeks, 3-7x/week, individual session duration | Not reported | No | 80 |
Fernandes 2017 [42] | Multimodal: exercise (resistance, proprioception and balance) | Physiotherapists | Outpatient—hospital | Not reported but ‘An attendance of 12 sessions or more was considered good compliance’, implying ≥ 6 weeks, 2x/week, for 60 min | Not reported | No | 351 (824 when including patient expenses) |
Gao 2015 [43] | Multimodal: exercise (inspiratory muscles, endurance) | Professional therapists | Inpatient | 3–7 days, 2x/day, for 50–60 min | Not reported | No | 246 |
Gränicher 2020 [44] | Multimodal: exercise (endurance, stretching and flexibility, resistance; individual exercises when indicated), counselling/education | Physiotherapists | Outpatient—hospital | 3–4 weeks, 1.25–3x/week, individual session duration | Low to moderate | No | 283 |
Howard 2019 [30] | Multimodal: promotion of physical activity, exercise (inspiratory muscles), nutrition (counselling), psychosocial (stress management), planning of care, smoking cessation | Not reported | Home | Individual; min 2 weeks, 3–7x/week, individual session duration | Not reported | No | 80 |
Huang 2012 [45] | Multimodal: exercise (resistance), counselling/education | Physiotherapists | Home | 4 weeks, 7x/week, for 40 min (first session); remaining sessions individual | Not reported | No | 20 |
Koh 2021 [46] | Multimodal: nutrition (supplements), exercise (resistance), counselling/education, drug evaluation, stabilising diseases | Dieticians, physiotherapists | Outpatient—community, hospitalc | 3 weeks, frequency not reported, individual session duration | Not reported | No | Not calculable |
Lai 2017 [32] | Multimodal: exercise (inspiratory muscles, endurance) | Inpatient | 1 week, 3 + 2 + 1/day, for 45–60 min plus breathing exercises | Not reported | No | Not calculable | |
Lai 2019 [33] | Multimodal: exercise (inspiratory muscles, endurance) | Specialised nurses, physical therapists | Inpatient | 1 week, 3 + 1/day, for 30 min plus breathing exercises | Not reported | No | Not calculable |
McGregor 2004 [47] | Unimodal: counselling/education, exercise (not specified) | Not reported | Home | 1–3 weeksc, unclear frequency, individual session duration | Not reported | No | 22 |
Mouch 2019 [31] | Multimodal: promotion of physical activity, exercise (inspiratory muscles), nutrition (counselling), psychosocial (stress management), planning of care, smoking cessation | Not reported | Home | Individual; min 2 weeks, 3-7x/week, individual session duration | Not reported | No | 54 |
Nguyen 2022 [48] | Multimodal: counselling/education, nutrition (counselling), psychosocial (stress management, anxiety reduction), exercise (resistance, stretching and flexibility, endurance, proprioception and balance) | Physiotherapist, instructor in physical activity, social worker, dietician, psychologist, occupational therapist | Outpatient—hospital, home | 8 weeks, 2x/week, for 60 min | Low | Yes | 60 |
Pham 2016 [49] | Multimodal: exercise (stretching and flexibility, resistance, endurance, proprioception and balance), counselling/education | Kinesiologist and/or Human Kinetics graduate student | Outpatient—community | 12 weeks, 3x/week, for 40–60 min | Moderate to high | Yes | 103 |
Ploussard 2020 [50] | Multimodal: counselling/education, planning of care, exercise (disease-specific), promotion of physical activity, stabilising diseases, psychological (other), nutrition (counselling, supplements) | Urology nurse, physiotherapist, nurse anaesthetist, oncology nurse specialist, cardiologist (if needed), pneumologist (if needed), psychologist, dietician, urologist | Home | 2 weeksc, 2–3x/day, for 1 full day, then individual session duration | Not reported | No | 231 |
Risco 2022 [51] | Multimodal: counselling/education, promotion of physical activity, exercise (endurance, resistance), nutrition (counselling, supplements), psychosocial (anxiety reduction, stress management, other) | Anaesthesiologists, physiotherapists, dietitians, psychologists and nurses | Outpatient—hospital | Min 4 weeks, 2-3x/week, for 47 min (endurance) and individual session duration (strength, physical activity) | High (endurance), moderate (strength) | Yes | 445 |
Tew 2017 [52] | Unimodal: exercise (endurance) | Research nurse, physiotherapist | Outpatient—hospital | 4 weeks, 3x/week, for 45 min (after first 3 sessions option to do it in 37 min) | High | Yes | 1341 |
Tveter 2020 [53] | Multimodal: counselling/education, other (assistive devices, orthoses), exercise (stretching and flexibility, resistance) | Occupational therapist | Home | 12 weeks, 3x/week, individual session duration | Moderate to high | Yes | Not reported |
Van Wijk 2020 [54] | Various (model): not reported, but assumedly: exercisec, promotion of physical activity, nutrition, stabilizing diseases, alcohol cessation, smoking cessation | Variable (model) | Not reported | Variable (model) | Not reported | No information | 1446 |
Wang 2020 [55] | Multimodal: exercise (inspiratory muscles), nutrition (counselling, supplements), counselling/education, planning of care, other (financial/social support) | Physiotherapist, dietician, case manager | Not reported | 2–4 weeks, 5x/week, for 30 min plus breathing exercises | Not reported | No | Not reported |
Zhou 2017 [34] | Multimodal: exercise (inspiratory muscles, endurance) | Lung cancer nurse specialists, physiotherapists | Inpatient | 1 week, 2 + 3 + 1x/day, for 65–70 min | Not reported | No | Not calculable |
Risk of bias and methodological quality
Results of individual economic evaluations
Study ID, main reference | Clinical effectiveness (IG vs. CG) | Total costs in EUR (2020) (IG vs. CG) | Cost-effectiveness based on direction of effectsa | Risk of bias/quality |
---|---|---|---|---|
Results from model-based economic evaluations | ||||
Results from CEAs | ||||
Dholakia 2021 [41] | Mortality: 397/4415 (9.0%) vs. 441/4415 (10.0%); RDb -1.0% | Mean 59,849 vs. 65,304; MDb -5455 | Cost-effective | ISPOR-Q: Insufficiently credible |
Results from CBAs | ||||
Chen 2022 [40] | Morbidity: 24/240 (10.0%) vs. 16/240 (6.7%); RDb -3.3% | Meanb 3292 vs. 3742; MDb -450 | Cost-effective; total cost–benefit: 108,022 EUR (2020) | ISPOR-Q: Sufficiently credible |
Van Wijk 2020 [54] | Morbidity: not reported | 28,001 vs. 30,242; difference -2,241c | Unclear (effectiveness not reported); return of investment: 1.55 | ISPOR-Q: Insufficient information |
Results from trial-based economic evaluations | ||||
Results from CUAs | ||||
AlShewaier 2016 [37] | QALYsd: Median 0.679 (IQR 0.10) vs. 0.573 (0.05); Difference in mediansb 0.106 | Median 20,790 vs. 19,952; difference in mediansb 838 | Unclear; incremental analysis required: ICER: 7906 EUR (2020) per QALY gained, but no WTP reported | RoB 2: High CHEC: 13/19 items |
Fernandes 2017 [42] | QALYsd: Mean 0.66 ± BS SE 0.04 vs. 0.61 ± 0.04e; MD 0.04 (95% CI 0.01 to 0.07) | Mean 17,432 ± BS SE 1265 vs. 17,574 ± 1480; MD -142 (95% CI -3952 to 3668) (331b when including patient expenses) | Cost-effective (unclear when including patient expenses); Probability of CEA at a WTP of 40,000 EUR: 84% (approx. 79% when including patient expenses) | RoB 2: Some concerns CHEC: 16/19 items |
Nguyen 2022 | QALYsd: Mean 0.7 ± SD 0.3 vs. 0.6 ± 0.3; MDb 0.1 | Mean 15,071 ± SD 7014 vs. 15,472 ± 6309; MD -401 | Cost-effective | RoB: Some concerns (QALY), high (costs) CHEC: 9/19 items |
Tveter 2020 [53] | QALYsd: Not reported per group; difference 0.07c | Not reported per group; difference -508c | Cost-effective | RoB 2: Some concerns (QALY), high (costs) CHEC: 11/19 items |
Results from CEAs | ||||
McGregor 2004 [47] | HrQoL: EQ-5D-3L VAS (0–100%)d: mean 75.80 ± SD 14.86 vs. 72.15 ± 22.20f; MDb 3.65%, EQ-5D-3L utilitiesd: mean 0.72 ± SD 0.13 vs. 0.60 ± SD 0.31f; MDb 0.12 | Mean 4148 vs. 5005; MDb -856 | Cost-effective | RoB 2: High CHEC: 8/19 items |
Tew 2017 [52] | HrQoL: EQ-5D-5L utilitiesd: mean 0.837 vs. 0.760; MD 0.077 (95% CI 0.005 to 0.148) | BS mean 14,269 ± SD 3542 vs. 13,688 ± 3542; BS MD 582 (95% CI -1588 to 2848) | Unclear; incremental analysis required, but ICER not reported | RoB 2: High CHEC: 14/19 items |
Results from CCAs | ||||
Barberan-Garcia 2019 [38] | HrQoL: SF-36 PCSd: mean 47 ± SD 7 vs. 44 ± 8; MDb 3 SF-36 MCS scored: mean 51 ± SD 9 vs. 50 ± 9; MDb 1 Morbidity: 19/62 (30.6%) vs. 39/63 (61.9%); RDb -31.3% Mortality: 1/62 (1.6%) vs. 4/63 (6.3%); RDb -4.7% PROMs: YPAS scored: mean 46 ± SD 13 vs. 39 ± 15; MDb 7 HAD total score: mean 6 ± SD 5 vs. 8 ± 6; MDb -2 | Mean 5428 (range 1792 to 30,532) vs. 6416 (1587 to 34,521); BS MD -955 (95% CI -3109 to 1033) | Cost-effective | RoB 2: Some concerns (morbidity, mortality), high (PROMs, costs) CHEC: not applicable |
Gao 2015 [43] | Morbidity: 12/71 (16.9%) vs. 59/71 (83.3%); RDb -66.4% | Mean 9728 ± SD 1130 vs. 8955 ± 888; MDb 773 | Unclear; incremental analysis required, but ICER not applicable for CCA | ROBINS-I: Serious CHEC: not applicable |
Gränicher 2020 [44] | PROMs: Lysholm Scored: mean 87.1 ± SD 9.0 vs. 69.1 ± 14.9; MDb 18 Lysholm Score pain itemd: mean 25.0 ± SD 0.0 vs. 16.5 ± 9.1; MDb 8.5 Tegner Activity Scaled: mean 3.8 ± SD 0.8 vs. 2.5 ± 0.9; MDb 1.3 Physical function: Stair climbing test, time in seconds: mean 12.58 ± SD 4.64 vs. 13.59 ± 5.30; MDb -1.01 Knee ROM (degrees)d: mean 100.5 ± SD 18.7 vs. 103.5 13.7; MDb -3 | Mean 3187 vs. 4052; MDb -865 | Unclear (inconsistent effectiveness); individual decision required | RoB 2: Some concerns (PROMs, physical function), high (costs) CHEC: not applicable |
Howard 2019 [30] | Morbidity: 12/40 (30.0%) vs. 29/75 (38.7%); RDb -8.7% Mortality: 1/40 (2.5%) vs. 1/75 (1.3%); RDb 1.2% | Mean 58,300 ± SD 42,590 vs. 75,248 ± 77,516; MDb (incorporating prehabilitation costs) -16,870 | Unclear (inconsistent effectiveness); individual decision required | ROBINS-I: Serious CHEC: not applicable |
Huang 2012 [45] | Morbidity: Infection rate: 2/126 (1.6%) vs. 1/117 (0.9%); RDb 0.7% Rate of deep vein thrombosis: 5/126 (4.0%) vs. 3/117 (2.6%); RDb 1.4% PROMs: Pain (VAS): mean 2.4 ± SD 0.7 vs. 2.5 ± 0.6; MDb -0.1 Physical function: Knee ROM (degrees)d: mean 76 ± SD 22 vs. 74 ± 20; MDb 2 Ambulation statusd: 108/126 (85.7%) vs. 95/117 (81.2%); RDb 4.5% | Mean 6726 ± SD 283 vs. 6841 ± SD 241; MDb (incorporating prehabilitation costs) -95 | Unclear (inconsistent effectiveness); individual decision required | RoB 2: High CHEC: not applicable |
Morbidity: 24/58 (41.4%) vs. 11/23 (47.8%); RDb -6.4% Mortalityg: 0/58 (0%) vs. 0/23 (0%); RDb 0% | Not reported per group; MD -2584 | Cost-effective | ROBINS-I: Serious CHEC: not applicable | |
Lai 2017 [32] | Morbidity: 5/51 (9.8%) vs. 14/50 (28.0%); RDb -18.2% | Mean 7677 ± SD 1374 vs. 8608 ± 2482; MDb -931 | Cost-effective | RoB 2: High CHEC: not applicable |
Lai 2019 [33] | Morbidity: 4/34 (11.8%) vs. 12/34 (35.3%); RDb -23.5% | Median 10,456 (IQR 9683 to 11,339) vs. 11,285 (10,544 to 13,340); Difference in mediansb -830 | Cost-effective | RoB 2: High CHEC: not applicable |
Ploussard 2020 [50] | Mortality: 0/194 (0%) vs. 1/156 (0.6%); RDb -0.6% | Mean 2904 vs. 3282; MDb -379 | Cost-effective | ROBINS-I: Serious CHEC: not applicable |
Risco 2022 [51] | Morbidity: Comprehensive complications index: mean 15.1 ± SD 17.1 vs. 16.6 ± 16.9; MDb: -1.5 | Mean 7288 vs. 7142; MD 145 | Unclear; incremental analysis required, but ICER not applicable for CCA | ROBINS-I: Serious CHEC: not applicable |
Wang 2020 [55] | Morbidity: 21/70 (30.0%) vs. 18/34 (52.9%); RD -22.9% Mortality: 1/70 (1.4%) vs. 1/34 (2.9%); RDb -1.5% PROMs (in subsample of n = 33 vs. n = 24): FACT-Hep scored: median 152 (range 102 to 179) vs. 148 (66 to 175); differences in mediansb 4 | Median 6138 (IQR 4590 to 8833) vs. 7349 (5328 to 11,026); difference in medians -1210 | Cost-effective | ROBINS-I: Serious CHEC: not applicable |
Zhou 2017 [34] | Morbidity: 36/197 (18.3%) vs. 194/742 (26.1%); RDb: -7.8% | Not calculable in EUR (2020) as original currency not reported; original values: mean 7131.8 ± SD 2316.6 vs. 77,266.4 ± 1615.0; MDb -134.60 | Cost-effective | ROBINS-I: Critical CHEC: not applicable |
Results from CMAs | ||||
Beaupre 2004 [39] | Not applicable | Mean 1285 ± SD 1196 vs. 1283 ± 1329; MD 2 | Not cost-effective | RoB 2: High CHEC: not applicable |
Englesbe 2017 [29] | Not applicable | Provider perspective: median 16,900 (IQR 10,162 to 30,365) vs. 23,091 (14,993 to 39,017); difference in mediansb -6191 Payer perspective: median 19,216 (IQR 12,122 to 33,840) vs. 24,519 (17,057 to 37,243); difference in mediansb -5303 | Cost-effective | ROBINS-I: Serious CHEC: not applicable |
Mouch 2019 [31] | Not applicable | Mean 24,435 ± SD 20,024 vs. 26,903 ± 24,935; MDb -2468 | Cost-effective | ROBINS-I: Moderate CHEC: not applicable |
Pham 2016 [49] | Not applicable | Reported only for a subset of patients (5/29 vs. 11/21): mean 5081 ± SD 298 vs. 5152 ± 656; MDb -71 | Cost-effective | RoB 2: High CHEC: not applicable |